To view the video full screen, click on the small button next to the volume control in the lower right hand corner.

Dept. of Hematology
University Medical Center Utrecht, the Netherlands

SUMMARY:
by Lynne Lederman, PhD

In HOVON studies of non-myeloablative allogeneic SCT, treatment related mortality has continued to decrease, and PFS has increased. Follow-up studies have established a graft vs. myeloma effect. Because there has been no plateau in PFS, it is possible that maintenance (e.g., with interferon) may improve survival. The presence or absence of graft vs. host disease (GVHD) , high levels of beta-2-microglobulin, deletion of chromosome 13, and t (4;14) were not prognostic factors. Donor lymphocyte infusion (DLI) is being administered to patients receiving non-myeloablative allogeneic SCT and lenalidomide maintenance in a study comparing this treatment to either bortezomib or thalidomide maintenance for patients without HLA-matched donors.